Photon Launches an At-Home Compounded GLP-1 Bioreactor

April 1, 2025 — Brooklyn, NY — Today, I’m proud to announce a milestone in personalized healthcare: the launch of the Photon Bioreactor. This prescription-only medical device enables patients to safely and effectively compound GLP-1 medications—including semaglutide, tirzepatide, and liraglutide—from the comfort of their own homes.

The Photon Bioreactor is the result of years of R&D at the intersection of synthetic biology, precision compounding, and patient empowerment. With this device, patients are no longer bound by cold chains or centralized manufacturing. Instead, they receive monthly ingredient shipments, enabling just-in-time compounding that’s both cost-effective and responsive to individual needs.

Starting today, April 1, licensed physicians across the United States can prescribe the Photon GLP-1 Bioreactor to eligible patients. The device is priced at $499 up front, with a $49/month subscription that covers everything needed for safe, consistent monthly synthesis.

“We believe medicine should adapt to the individual, not the other way around,” said Otto Sipe, CEO of Photon. “The Photon Bioreactor marks a paradigm shift—from factory-made, one-size-fits-all medications to personalized, in-home bio-manufacturing. It’s the beginning of a future where treatment is more adaptive, accessible, and aligned with the biology of each patient.”

Photon’s platform is built with rigorous safety protocols and regulatory compliance at its core. Each Photon Bioreactor is locked to the patient’s prescription profile, with dose parameters verified via onboard sensors and cloud-connected safeguards. The monthly ingredient kits are precision-matched to each prescription, and all data is accessible to prescribing clinicians via the Photon Health Dashboard.

The Photon Bioreactor is designed with multiple layers of clinical safety and regulatory compliance. When prescribed by a licensed provider, the system enables patients to:

• Access sterile compound FDA-approved peptides with built-in micro-fluidic purification
• Adjust and titrate doses based on clinician-directed protocols
• Track biomarkers and dosing trends via seamless integration with Photon’s mobile platform
• Minimize cost, compared to traditional compounded formulations

For patients prescribed GLP-1 therapies for metabolic conditions, appetite regulation, or diabetes management, the Photon Bioreactor offers convenience, control, and continuity. No more refrigeration anxiety, pharmacy delays, or insurance chaos—just personalized medication, on demand.

Clinicians interested in prescribing the Photon At-Home Compounded GLP-1 Bioreactor can access our clinical portal today at app.photon.health.

This is only the beginning. As we continue building the tools to rewire healthcare around the individual, we’ll stay rooted in our core belief: medicine works best when it’s personal.

— Otto Sipe
CEO, Photon

*Please note: this is an April’s Fool joke, and thus, it is not a real announcement. We understand the difficulties that people face today in accessing medication at affordable prices, and this spoof intends to call attention to this reality. We also understand the dangers and repercussions of producing medications at home and do not intend to promote it.